Somatostatin analogs for pancreatic neuroendocrine tumors: any benefit when KI-67 is ≥10%?
Alonso Gordoa, T.
Zandee, W. T.
Laskaratos, F. M.
de Mestier, L.
Cwikla, J. B.
de Herder, W. W.
van Leeuwaarde, R. S.
AffiliationDepartment of Gastroenterology, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy.
MetadataShow full item record
AbstractBackground: Long-acting somatostatin analogs (SSAs) are the primary first-line treatment of well-differentiated advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but data about their efficacy in pancreatic NETs (panNETs) with Ki-67 ≥10% are still limited. Materials and methods: To assess the clinical outcomes of advanced, non-functioning, well-differentiated panNETs with Ki-67 ≥10% receiving first-line long-acting SSAs in a real-world setting, we carried out a retrospective, multi-center study including patients treated between 2014-2018 across ten centers of the NET CONNECT Network. The primary endpoints were time to next treatment (TNT) and progression-free survival (PFS), while overall survival (OS) and treatment safety were secondary endpoints. Results: 73 patients were included (68 G2, 5 G3), with liver metastases in 61 cases (84%). After a median follow-up of 36.4 months (range, 6-173 months), the median TNT and PFS were 14.2 months (95% CI, 11.6-16.2 months) and 11.9 months (95% CI, 8.6-14.1 months) respectively. No statistically significant difference was observed according to the somatostatin analog used (octreotide vs lanreotide), while increased tumor grade (HR: 4.4, 95% CI, 1.2-16.6; p=0.04) and hepatic tumor load (HR: 2, 95% CI, 1-4; p=0.03) were independently associated with shortened PFS. The median OS recorded was 86 months (95% CI, 56.8-86 months), with poor outcomes observed when the hepatic tumor burden was >25% (HR: 3.4, 95% CI, 1.2-10; p=0.01). Treatment-related adverse events were reported in 14 patients, most frequently diarrhea. Conclusions: SSAs exert antiproliferative activity in PanNETs with Ki-67 ≥10%, particularly in G2 tumors, as well as when hepatic tumor load is ≤25%.
CitationMerola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E, Kolasinska-Cwikla A, et al. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is >/=10%? Oncologist. 2020.
- Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
- Authors: Allaw MB, Switchenko JM, Khalil L, Wu C, Alese OB, Akce M, Draper A, Jones AT, El-Rayes B, Shaib W
- Issue date: 2022
- Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
- Authors: Diamantopoulos LN, Laskaratos FM, Kalligeros M, Shah R, Navalkissoor S, Gnanasegaran G, Banks J, Smith J, Jacobs B, Galanopoulos M, Mandair D, Caplin M, Toumpanakis C
- Issue date: 2021
- External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
- Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A, Benavent M, Alonso V, Riesco MDC, Alonso-Gordoa T, Custodio A, Sanchez Canovas M, Hernando J, López C, La Casta A, Fernandez Montes A, Marazuela M, Crespo G, Diaz JA, Feliciangeli E, Gallego J, Llanos M, Segura A, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle J, Garcia-Carbonero R
- Issue date: 2022
- The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
- Authors: Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ
- Issue date: 2017 Mar
- [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
- Authors: Bencsiková B
- Issue date: 2016